PetMedix, recognized as an R&D stage veterinary therapeutics biotechnology company, is situated in Cambridge, UK. Founded in 2017, the company has carved a niche in the Biotechnology and Health Care sectors, specializing in innovative treatments for animals.
The company recently announced an upcoming collaboration with Zoetis, a significant transition that may enhance its offerings and market reach.
In terms of funding, PetMedix secured a robust £27.00M Series B investment on 08 September 2021, drawing the attention of prominent investors such as Parkwalk Advisors, Cambridge Innovation Capital, Digitalis Ventures, Kyoritsu Corporation, and Tencent. Such backing underscores the confidence in PetMedix's potential for growth and innovation within the veterinary biotechnology space.